BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19509354)

  • 41. Targeted therapies for kidney cancer in urologic practice.
    Haas NB; Uzzo RG
    Urol Oncol; 2007; 25(5):420-32. PubMed ID: 17826664
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Vascular and renal effects of anti-angiogenic therapy].
    Halimi JM; Azizi M; Bobrie G; Bouché O; Deray G; des Guetz G; Lecomte T; Levy B; Mourad JJ; Nochy D; Oudard S; Rieu P; Sahali D
    Nephrol Ther; 2008 Dec; 4(7):602-15. PubMed ID: 19027389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Targeted therapies: sequential and combined treatments].
    Gross-Goupil M; Escudier B
    Bull Cancer; 2010; 97():65-71. PubMed ID: 20418205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of adverse effects of anti-VEGF therapy for cancer.
    Kamba T; McDonald DM
    Br J Cancer; 2007 Jun; 96(12):1788-95. PubMed ID: 17519900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Cutaneous side effects of antiangiogenic agents].
    Robert C
    Bull Cancer; 2007 Jul; 94 Spec No():S260-4. PubMed ID: 17846013
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion.
    Nowak-Sliwinska P; Weiss A; van Beijnum JR; Wong TJ; Ballini JP; Lovisa B; van den Bergh H; Griffioen AW
    J Cell Mol Med; 2012 Jul; 16(7):1553-62. PubMed ID: 21880113
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The role of angiogenesis in renal carcinoma].
    Bussolati B; Satolli MA; Camussi G
    G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Angiogenesis and renal cell carcinoma].
    Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
    de Mulder PH; Haanen JB; Sleijfer S; Kruit WH; Gietema JA; Richel DJ; Groenewegen G; Voest EE; van den Eertwegh AJ; Osanto S; Jansen RL; Mulders PF
    Ned Tijdschr Geneeskd; 2008 Feb; 152(7):371-5. PubMed ID: 18380383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel agents for the treatment of advanced kidney cancer.
    Cooney MM; Remick SC; Vogelzang NJ
    Clin Adv Hematol Oncol; 2004 Oct; 2(10):664-70. PubMed ID: 16163253
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence of efficacy: researchers investigating markers for angiogenesis inhibitors.
    Brower V
    J Natl Cancer Inst; 2003 Oct; 95(19):1425-7. PubMed ID: 14519742
    [No Abstract]   [Full Text] [Related]  

  • 52. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
    Robert C; Faivre S; Raymond E; Armand JP; Escudier B
    Ann Intern Med; 2005 Aug; 143(4):313-4. PubMed ID: 16103482
    [No Abstract]   [Full Text] [Related]  

  • 53. [Advanced renal carcinomas with special situations. How to treat them?].
    Pouessel D; Patard JJ; Culine S
    Bull Cancer; 2010; 97():83-90. PubMed ID: 20418207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Compounds in clinical Phase III and beyond.
    Kessler T; Bayer M; Schwöppe C; Liersch R; Mesters RM; Berdel WE
    Recent Results Cancer Res; 2010; 180():137-63. PubMed ID: 20033382
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
    Sire M; Wallerand H; Kilkoski F; Grenier N; Ferrière JM; Ravaud A
    Bull Cancer; 2008 Sep; 95(9):813-20. PubMed ID: 18829413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted drugs for metastatic renal cell carcinoma.
    Motzer RJ; Basch E
    Lancet; 2007 Dec; 370(9605):2071-3. PubMed ID: 18156012
    [No Abstract]   [Full Text] [Related]  

  • 57. Prognostic factors in patients treated with VEGF-targeted therapies.
    Choueiri TK
    Clin Adv Hematol Oncol; 2010 Feb; 8(2):92-3. PubMed ID: 20386528
    [No Abstract]   [Full Text] [Related]  

  • 58. [Anti-angiogenetic agents for solid tumors].
    Blay JY
    Rev Med Interne; 2007 Jun; 28 Suppl 1():S7-8. PubMed ID: 17482319
    [No Abstract]   [Full Text] [Related]  

  • 59. Angiogenesis as targeted breast cancer therapy.
    Hayes DF; Miller K; Sledge G
    Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Oncology 2008].
    Stemmler HJ; Heinemann V
    Dtsch Med Wochenschr; 2008 Jun; 133(25-26):1395-9. PubMed ID: 18521794
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.